Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
Holston Medical Group, PC
mi
from
Kingsport, TN
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
Holston Medical Group, PC
mi
from
Kingsport, TN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
New Phase Research & Development
mi
from
Knoxville, TN
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
New Phase Research & Development
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
Clinical Research Solutions - Smyrna, TN
mi
from
Smyrna, TN
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
Clinical Research Solutions - Smyrna, TN
mi
from
Smyrna, TN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
Health Innovation Research Group
mi
from
Arlington, TX
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
Health Innovation Research Group
mi
from
Arlington, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
Inquest Clinical Research
mi
from
Baytown, TX
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
Inquest Clinical Research
mi
from
Baytown, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
VA North Texas Health Care System - Dallas VA Medical Center (DVAMC)
mi
from
Dallas, TX
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
VA North Texas Health Care System - Dallas VA Medical Center (DVAMC)
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
San Antonio Premier Internal Medicine
mi
from
San Antonio, TX
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
San Antonio Premier Internal Medicine
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
Bandera Family HealthCare Research, LLC (BFHC)
mi
from
San Antonio, TX
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
Bandera Family HealthCare Research, LLC (BFHC)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated:  12/31/1969
Cardiovascular Associates Ltd
mi
from
Virginia Beach, VA
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Status: Enrolling
Updated: 12/31/1969
Cardiovascular Associates Ltd
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Alirocumab in Patients With Acute Myocardial Infarction
Alirocumab in Patients With Acute Myocardial Infarction: A Randomized Controlled Double-Blinded Study
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Alirocumab in Patients With Acute Myocardial Infarction
Alirocumab in Patients With Acute Myocardial Infarction: A Randomized Controlled Double-Blinded Study
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Icahn School of Medicine
mi
from
New York, NY
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Icahn School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Sterling Research Group
mi
from
Cincinnati, OH
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Sterling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Wellmont CVA Heart Institute
mi
from
Greeneville, TN
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Wellmont CVA Heart Institute
mi
from
Greeneville, TN
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Amarillo Heart Clinical Research Institute Inc.
mi
from
Amarillo, TX
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Amarillo Heart Clinical Research Institute Inc.
mi
from
Amarillo, TX
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
National Clinical Research, Inc.
mi
from
Richmond, VA
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
National Clinical Research, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
St. Paul's Hospital
mi
from
Vancouver,
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
St. Paul's Hospital
mi
from
Vancouver,
Click here to add this to my saved trials
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Status: Enrolling
Updated:  12/31/1969
Investigational Site Number 124704
mi
from
Quebec,
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase
Status: Enrolling
Updated: 12/31/1969
Investigational Site Number 124704
mi
from
Quebec,
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Encompass Clinical Research
mi
from
Encinitas, CA
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Encompass Clinical Research
mi
from
Encinitas, CA
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Integrated Research Center, Inc.
mi
from
San Diego, CA
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Integrated Research Center, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Ventura Clinical Trials
mi
from
Ventura, CA
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Ventura Clinical Trials
mi
from
Ventura, CA
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Colorado Springs Health Partners, Pc
mi
from
Colorado Springs, CO
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Colorado Springs Health Partners, Pc
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Meridien Research - Bradenton
mi
from
Bradenton, FL
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Meridien Research - Bradenton
mi
from
Bradenton, FL
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Meridien Research - Lakeland
mi
from
Lakeland, FL
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Meridien Research - Lakeland
mi
from
Lakeland, FL
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Oviedo Medical Research, LLC
mi
from
Oviedo, FL
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Oviedo Medical Research, LLC
mi
from
Oviedo, FL
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Meridien Research- Tampa
mi
from
Tampa, FL
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Meridien Research- Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
River Birch Research Alliance
mi
from
Blue Ridge, GA
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
River Birch Research Alliance
mi
from
Blue Ridge, GA
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Drug Studies America
mi
from
Marietta, GA
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Drug Studies America
mi
from
Marietta, GA
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Herman Clinical Research
mi
from
Suwanee, GA
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Herman Clinical Research
mi
from
Suwanee, GA
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Cedar-Crosse Research Center
mi
from
Chicago, IL
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Cedar-Crosse Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates
mi
from
Newton, KA
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates
mi
from
Newton, KA
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
University of Maryland Medical Center
mi
from
Baltimore, MD
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Centennial Medical Group
mi
from
Elkridge, MD
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Centennial Medical Group
mi
from
Elkridge, MD
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
MD Medical Research
mi
from
Oxon Hill, MD
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
MD Medical Research
mi
from
Oxon Hill, MD
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Mercury Street Medical
mi
from
Butte, MT
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Mercury Street Medical
mi
from
Butte, MT
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Einstein Clinical Research
mi
from
Charlotte, NC
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Einstein Clinical Research
mi
from
Charlotte, NC
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Triad Clinical Trials, LLC
mi
from
Greensboro, NC
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Triad Clinical Trials, LLC
mi
from
Greensboro, NC
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
PMG Research of Wilmington
mi
from
Wilmington, NC
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
PMG Research of Wilmington
mi
from
Wilmington, NC
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Sterling Research Group
mi
from
Cincinnati, OH
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Sterling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Wells Institute For Health Awareness
mi
from
Kettering, OH
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Wells Institute For Health Awareness
mi
from
Kettering, OH
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Ohio Clinical Research-Lyndhurst
mi
from
Lyndhurst, OH
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Ohio Clinical Research-Lyndhurst
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated:  12/31/1969
Awasty Research Network, LLC
mi
from
Marion, OH
Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: Enrolling
Updated: 12/31/1969
Awasty Research Network, LLC
mi
from
Marion, OH
Click here to add this to my saved trials